U.S., Jan. 24 -- ClinicalTrials.gov registry received information related to the study (NCT07364448) titled 'A Study to Evaluate the Safety of Hydronidone Capsules in Patients With Liver Fibrosis' on Jan. 16.
Brief Summary: This is an open-label, single-arm study designed to collect safety data on hydronidone capsules in patients with chronic hepatitis B virus infection accompanied by liver fibrosis or fatty liver disease accompanied by liver fibrosis .
Approximately 200 subjects will be enrolled, all of whom will receive hydronidone capsules three times daily, with three capsules per dose, resulting in a total daily treatment dose of 270 mg. The medication will be administered orally half an hour before meals for a total of 28 days.
Stu...